Business
VALEO PHARMA PROVIDING GUIDANCE OF RECORD REVENUES FOR THE SECOND QUARTER 2023
VALEO PHARMA PROVIDING GUIDANCE OF RECORD REVENUES FOR THE SECOND QUARTER 2023.
About this update from Valeo Pharma Inc.
[{"type":"text","content":"\n\n\n\nVALEO PHARMA PROVIDING GUIDANCE OF RECORD REVENUES FOR THE SECOND QUARTER 2023\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nVALEO PHARMA PROVIDING GUIDANCE OF RECORD REVENUES FOR THE SECOND QUARTER 2023\nCanada NewsWire\nMONTREAL, May 25, 2023\n\n\n\nQ2-23 revenues to exceed $13.5 millionQ2-23 adjusted EBITDA loss to decrease below $2.0 millionQ2-23 operating expenses to remain in line with prior quartersENERZAIR® and ATECTURA® quarterly revenues grow 270% over prior yearMONTREAL, May 25, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (\"Valeo\" or the \"Company\"), a Canadian pharmaceutical company, today provided a financial and commercial update ahead of its second quarter 2023 results.\n\n \n \n \n \n \n \n\n \nQ2-23 Financial Update:\nBased on currently available information, the Company is providing the following guidance updates for its second quarter 2023. The Company expects:\nRevenues to exceed $13.5 million, a sixth consecutive quarter of revenue growth and a quarterly recordAdjusted EBITDA loss to drop below $2.0 million, a sixth consecutive quarter of adjusted EBITDA loss reductionOperating expenses to remain in line with prior quarters\"We are displaying continued quarterly revenue growth and overall improvement in our financial performance. Our core products have grown significantly on a year-over-year basis and we see continuing gains ahead. We are especially pleased with the increased physician and patient adoption of our innovative asthma therapies which have long growth runways ahead of them\", said Steve Saviuk, CEO.  \"Our business development efforts are focused on adding additional core products in the near term to leverage our operational and commercial platform and accelerate our timeline to profitability\".\nQ2-23 Commercial Update:\nOn the commercial front, the Company is pleased to report that:\nENERZAIR® and ATECTURA® total number of prescribing physicians (generalists and specialists) continued to grow and is now expected to exceed 2,000 at the end of April, 2023ENERZAIR® and ATEC...